These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12709295)

  • 41. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
    Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
    J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
    Chanchlani N; Russell RK
    Aliment Pharmacol Ther; 2024 Jul; 60(1):93-94. PubMed ID: 38773786
    [No Abstract]   [Full Text] [Related]  

  • 45. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence.
    Feagan BG; Kozma CM; Slaton TL; Olson WH; Wan GJ
    J Med Econ; 2014 Dec; 17(12):872-80. PubMed ID: 25162777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice.
    Virkki LM; Konttinen YT; Peltomaa R; Suontama K; Saario R; Immonen K; Jäntti J; Tuomiranta T; Nykänen P; Hämeenkorpi R; Heikkilä S; Isomäki P; Nordström D
    Clin Exp Rheumatol; 2008; 26(6):1059-66. PubMed ID: 19210870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P; Kawalec P; Pilc A
    Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inadvertent conception during concomitant treatment with infliximab and methotrexate in a patient with Crohn's disease: is the game worth the candle?
    Angelucci E; Cesarini M; Vernia P
    Inflamm Bowel Dis; 2010 Oct; 16(10):1641-2. PubMed ID: 20186946
    [No Abstract]   [Full Text] [Related]  

  • 51. Patient with severe Crohn's disease became a father while on methotrexate and infliximab therapy.
    Lamboglia F; D'Incà R; Oliva L; Bertomoro P; Sturniolo GC
    Inflamm Bowel Dis; 2009 May; 15(5):648-9. PubMed ID: 18777574
    [No Abstract]   [Full Text] [Related]  

  • 52. [Biologicals first-line in chronic inflammatory bowel disease? No].
    Herrlinger K; Stange EF
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1789. PubMed ID: 21882135
    [No Abstract]   [Full Text] [Related]  

  • 53. Infliximab.
    Valle E; Gross M; Bickston SJ
    Expert Opin Pharmacother; 2001 Jun; 2(6):1015-25. PubMed ID: 11585004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
    Ollendorf DA; Lidsky L
    Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
    Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
    Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials.
    Huang ML; Ran ZH; Shen J; Li XB; Xu XT; Xiao SD
    J Dig Dis; 2011 Jun; 12(3):165-72. PubMed ID: 21615869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infliximab treatment for Crohn's disease.
    Conroy CA; Cattell R
    Postgrad Med J; 2001 Jul; 77(909):436-40. PubMed ID: 11423591
    [No Abstract]   [Full Text] [Related]  

  • 58. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Dig Dis Sci; 2015 Sep; 60(9):2762-70. PubMed ID: 25673037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recommendations for the prevention and management of tuberculosis in patients taking infliximab.
    Salmon-Ceron D; ;
    Ann Med Interne (Paris); 2002 Nov; 153(7):429-31. PubMed ID: 12598827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.